Bangalore, 6th August 2026: Healthcare Global Enterprises Limited (HCG), (NSE: HCG, BSE: 539787), India’s largest dedicated cancer private hospital network, under the brand “HCG”, has today announced its financial results for the quarter ended 30th June 2026.
RESULTS HIGHLIGHTS (Consolidated)
Notes:
- Adjusted EBITDA excludes ESOP and one-time expenses, however in Q1 FY27 it also excludes North Bangalore Loss of INR 70 Mn
- Q4FY26 PAT post non-controlling interest normalized for one-time exceptional item pertaining goodwill impairment of fertility business
Dr. B. S. Ajaikumar, Founder and Non-Executive Chairman, HealthCare Global Enterprises Ltd., said
“The strong start to FY27 reflects the resilience of HCG’s integrated oncology model and our unwavering commitment to clinical excellence. Over the years, we have consistently invested in expanding access to advanced cancer care while building an institution that combines cutting-edge technology, world-class medical expertise, and compassionate patient care. As we continue to strengthen our network through strategic capacity expansion and focused investments in innovation, we remain committed to shaping the future of oncology and delivering sustainable long-term value for our patients, clinicians, shareholders, and the communities we serve.”
Commenting on the results, Dr. Manish Mattoo, Executive Director & CEO, HealthCare Global Enterprises Limited (HCG), said, “We have started FY27 on a strong note, with revenue growing 13% year-on-year to ₹6,951 million. Excluding North Bangalore hospital, 16 of our 25 centres recorded their highest-ever quarterly revenues, reflecting broad-based growth across our network and sustained demand for our oncology services.
Our focus on increasing the share of high-complexity oncology care and non-institutional business continues to strengthen the quality of our revenue. Non-institutional revenue grew 17% year-on-year, with its contribution increasing from 67% to 69%, while Adjusted EBITDA, grew 20% to ₹1,339 million, with margins improving to 19.4%.
We are encouraged by the strong response to our new North Bangalore hospital, which is expected to contribute meaningfully as insurance empanelment progress and onboarded doctors ramp up their practices. Looking ahead, we remain committed to strengthening clinical leadership, expanding capacity in high-potential markets, and delivering sustainable, profitable growth while enhancing access to world-class cancer care.”
Consolidated Highlights for the Quarter Ending 30th June, 26:
- HCG delivered revenue of INR 6,951 Mn in Q1 FY27, reflecting ~13% YoY growth. North Bangalore hospital commenced operations in May 26, contributed INR 67 Mn in Q1 FY27
- Revenue growth during the quarter was led by volume growth of 11% YoY. ARPP grew by 2% YoY, an improvement driven by a favourable payor mix was partly offset by changes in case mix, including a lower contribution from high-value, low-margin therapies
- Adjusted EBITDA was INR 1,339 Mn in Q1 FY27, up 20% YoY. EBITDA margins improved to 19.4% in Q1 FY27 compared to 18.2% in Q1 FY26
- International business revenue was INR 208 Mn, grew ~9% YoY in Q1 FY27, driven by stronger patient inflows for radiation oncology and PET cases
- Fertility Business divested in June 26; delivered revenue of INR 169 Mn and EBITDA of INR 23 Mn in Q1 FY27
Key Business Developments for the Quarter Ending 30th June, 26:
- Successfully commissioned the state-of-the-art 120+ bed hospital in North Bangalore, Hebbal, in May 2026, with 56 beds operational in the first phase. The facility has witnessed encouraging early traction, recording 550+ New patient registration and 300+ admissions since launch. The MR Linac was commissioned in July 2026, making the centre home to one of India’s most advanced adaptive radiation therapy platforms, further enhancing clinical capabilities and supporting future patient volume growth
- Total 121 operational beds added during the quarter comprising of 56 beds at North Bangalore, 26 beds at Ranchi, 19 at Borivali, 8 at Nashik, 5 at Hubli, 7 at Kenya, further strengthening capacity across the network
- Rajkot hospital has now become a Comprehensive Cancer Care (CCC) Centre following the commissioning of a new LINAC, strengthening its ability to provide advanced, end-to-end oncology care
- Expanded robotic surgery capabilities with the addition of two high-end surgical robotic systems, a new installation at Nashik and a replacement robot installed at Bangalore CoE, reinforcing HCG’s leadership in advanced oncology care
About Healthcare Global Enterprises Limited (HCG):
HealthCare Global Enterprises Ltd. (HCG), headquartered in Bengaluru, is the largest provider of cancer care in India. Through its network of 26 hospitals across India and Africa, HCG has brought advanced cancer care to the doorstep of millions of people. HCG’s comprehensive cancer centers provide expertise and advanced technologies for the effective diagnosis and treatment of cancer under one roof.
For updates and specific queries, please visit www.hcgel.com or feel free to contact
Healthcare Global Enterprises Limited
Ravi Gothwal – Head Investor Relations
Ph: +91-95996 55711
Email: Ravi.gothwal@hcgel.com
CDR India
Anoop Poojari / Suraj Digawalekar
Ph.: +91 98330 90434 / 98211 94418
Email: anoop@cdr-india.com / suraj@cdr-india.com
Safe Harbor
This document may contain forward-looking statements about Healthcare Global Enterprises Limited and its Subsidiaries, which are based on the beliefs, opinions, and expectations of the company’s management as the date of this Investor release and the companies do not assume any obligation to update their forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. These statements are not the guarantees of future performance and involve risks and uncertainties that are difficult to predict. Consequently, readers should not place any undue reliance on such forward-looking statements.